The efficacy and safety of tislelizumab combined with bevacizumab and second-line chemotherapy in the treatment of RAS-mutant metastatic colorectal cancer: a single arm, phase II study
收藏NIAID Data Ecosystem2026-03-14 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/82872
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Experimental Arm: tislelizumab combined with bevacizumab and second-line chemotherapy
Primary outcome(s): 6-month progression free survival (PFS) rate
Study Design: Single arm
创建时间：
2022-12-15
